Why Seniors Are Paying More as Drug Prices Fall
As federal and state policymakers grapple with how to lower prescription drug prices, they should work to ensure that patients, particularly seniors, have greater access to and realize the full benefit of lower-priced generic drugs. Increasingly, Medicare Part D plans are putting generic drugs into higher formulary tiers to compensate for escalating brand-name drug prices. […]
Patients Can See Their Savings
America’s patients can now see how much they save by treating their health conditions using generic drugs thanks to new data pulled from this year’s Generic Access and Savings Report in the United States. For the first time ever, the Association for Accessible Medicines (AAM) is releasing savings data for 20 common patient conditions, demonstrating the […]
AAM Statement on Importation Task Force
WASHINGTON DC (July 19, 2018) – Secretary Azar testified on June 26 before the Senate Finance Committee, policy makers should examine whether the U.S. is “underpaying for and under-reimbursing for generics. We need a strong, robust generic market. We may be driving those prices so low that we’re creating manufacturing anomalies that lead to sole-source […]
Highlights from Craig Burton on the Newly Released 2018 Generic Drug Access & Savings Report
AAM’s VP Policy Craig Burton shares the release of the 2018 Generic Drug Access & Savings in the U.S. report, which focused this year on savings from patient utilization of generic drugs. The report highlights 3 important findings: 9 out of every 10 prescriptions in the U.S. are generic drugs 93% of generic prescriptions are […]
AAM Provides Comments in Response to Administration’s Blueprint on Drug Pricing
Generic and Biosimilars Competition Drives Lower Prices and Reduced Out-of-Pocket Costs for Patients Washington DC (July 16, 2018)—The Association for Accessible Medicines (AAM) and the Biosimilars Council have today filed comments on the Trump Administration’s drug pricing blueprint. The Blueprint identifies four overarching goals for lowering drug prices: increasing competition; better negotiation; creating incentives for […]
Generic Drug Competition Lowers Prescription Cost to $6 on Average, Study Finds
Generic Pharmaceutical Industry Releases 10th Annual Access and Savings Report Shows Savings from Generic and Biosimilar Medicines at Risk WASHINGTON DC (July 10, 2018) – Today, the Association for Accessible Medicines (AAM) released its “Generic Access and Savings Report in the United States 2018,” which finds that 93 percent of generic prescriptions are filled at $20 […]
AAM Statement in Response to Secretary Azar’s Testimony Before Senate Finance Committee
WASHINGTON DC (June 26, 2018) – Secretary Azar’s testimony today highlighted two very important issues when it comes to reducing prescription drug prices in the United States. First, Secretary Azar noted that anticompetitive tactics used by brand-name manufacturers distort the market and keep prices artificially high. Notably, Secretary Azar endorsed the aims of the bipartisan CREATES […]
NYT: Generic Drug Prices Are Falling, but Are Consumers Benefiting?
Chip Davis has been out speaking with the media about the importance of generic and biosimilar medicines to patients and our economy. He is shining a light on the need to remedy anti-competitive roadblocks facing generics and biosimilars before they make it to market, and the challenges approved drugs meet when presented by consolidation on […]
AAM Responds to President Trump’s Speech on Lowering Prescription Drug Prices
Generic and Biosimilar Competition Is Cornerstone of President Trump’s Blueprint to Lower Drug Prices for American Patients
Administration’s Plan Embraces Getting More Generic and Biosimilar Medicines to Patients WASHINGTON DC (May 11, 2018) – In President Trump’s remarks today at the White House, he made clear the essential role that generic and biosimilar medicines play in containing prescription drug costs for patients. “President Trump’s embrace of generic and biosimilar competition as a […]
Dear Mr. President—On the Eve of Your Drug-Pricing Speech
A virtuous cycle of innovation and access has served as the foundation for our nation’s prescription drug market since the presidency of Ronald Reagan. When that market worked as Congress originally intended around the time of enactment of the Hatch-Waxman amendments in the 1980s, patients benefited from lifesaving new drugs; they maintained their health with […]
Skyrocketing Brand Drug Prices Are a Threat to Everyone
Prescription drugs treat conditions and improve patient health. But when drug prices are too high, access to medicines becomes out of reach for far too many patients.This crisis is fueled by the high launch prices of new brand biologics and year-over-year price increases of brand drugs that face no competition in the market for many […]
